RUNX1 and acute myeloid leukemia: This study explores the safety and efficacy of a novel conditioning regimen incorporating olaparib (a PARPi) for relapsed/refractory RUNX1::RUNX1T1+ AML patients undergoing allo-HSCT.<h4>Methods</h4>A retrospective analysis was conducted on six relapsed/refractory RUNX1::RUNX1T1+ AML patients treated between June 2022 and October 2023 at Beijing Lu Daopei Hospital.